CORXEL Pharmaceuticals CEO Sandy Mou Named to Fortune China’s Most Powerful Women: Next-Gen
Shanghai, China – September 10, 2026 – Fortune China announced its 2026 Most Powerful Women China list today. Sandy Mou, M.D., Executive Director of the Board and Chief Executive Officer of CORXEL Pharmaceuticals, was once again named to the “Most Powerful Women: Next-Gen” list. This marks Ms. Mou’s second consecutive year of receiving this recognition, underscoring the continued acknowledgement of her leadership in advancing CORXEL’s global development.
“Being named to this list again is not only an honor, but also a source of encouragement,” said Ms. Mou. “Biopharmaceutical innovation is becoming an important global calling card for China. Enabling more globally valuable innovative breakthroughs to reach the world and benefit patients worldwide is not only an aspiration of those committed to innovative drug development, and it is also the path CORXEL has consistently pursued.”
Since assuming the role of CEO of CORXEL Pharmaceuticals in January 2023, Ms. Mou has led the company as it focuses on the significant unmet medical needs in cardiometabolic diseases, while accelerating the global clinical development of CORXEL’s innovative pipeline.
“The globalization of China’s innovative medicines is taking shape through increasingly diverse pathways. For CORXEL, globalization means more than bringing products to overseas markets; it means building the capabilities to conduct high-quality clinical development in major global markets, compete internationally, and align with global regulatory and clinical systems,” Ms. Mou noted. “This is a longer and more challenging path—one that requires greater capital support and stronger team execution. But we believe that only innovation validated against global standards can truly go the distance. Through CORXEL’s own practice, we hope to give more Chinese innovative drug companies the confidence and conviction to continue pursuing global clinical development, and to explore broader possibilities for bringing China’s innovative medicines to the global market.”
Additional information
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. CORXEL is led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs). CORXEL’s diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications. CORXEL is developing selective small molecule compounds across the cardiometabolic spectrum with the lead product candidate CX11, an oral small molecule GLP-1 RA under clinical development for obesity and overweight conditions and T2DM, JX10, a thrombolytic and anti-inflammatory agent for acute ischemic stroke and CX12, an oral small molecule amylin RA under pre-clinical development. CORXEL also has additional small molecule programs in development targeting validated obesity targets.
* "CORXEL" or "CORXEL Pharmaceuticals" refers to the CORXEL Group.
For further information about CORXEL, please visit www.corxelbio.com.
